 |
 |
|
An early Christmas gift: The Autumn/Winter 2006 Drug Delivery ReportDear Customers, It's almost the end of the year and you'll be pleased to know that your copy of the Drug Delivery Report is on its way to you now. The current issue of the report discusses the renewed focus on needle-free injections in the drug delivery market, in addition to other innovative technologies and drug discovery platforms. Information from Glide Pharma, Aegis and 3M is also provided. As always, we hope the new issue of Drug Delivery Report E-News will be informative and a useful resource for you to use in your deal making activities. Given that deal activity appears to be increasing as the end of the year approaches, this month's news and trends round up will be even more important to those following the changing drug delivery landscape. Best wishes, |
||
 |
 |
Market News and TrendsDuring November 2006, PharmaDeals® Agreements recorded a total of 24 deals relating to drug delivery, six more than the number recorded for the previous month. Although start-up and emerging companies were involved in 19 of these agreements, only 6 of these deals were made with fellow start-up companies: 3 transactions were made with academic institutions; 5 with established companies; and 5 with global companies. Unusually, in comparison with the previous 10 months, global organisations were involved in 7 deals. Established companies were also more active in drug delivery deal making during November than in recent months. A full range of deal types was represented in November, with licensing, rights and technology access agreements the most common. Several deals had high potential financial values, a fact which is, arguably, not surprising considering the size of some of the companies involved in November's drug delivery deals. Read more... |
||
|
|
||
Featured ArticlePushing the Boundaries of Needle-free InjectionA need for alternative ways to deliver the growing list of new biopharmaceutical and molecular entities, such as vaccines, DNA-based therapies, peptides and proteins that cannot be administered orally has provided renewed focus on needle-free injections. In this article, Simon Bennett and Charles Potter of Glide Pharma, discuss the benefits of needle-free injection and the challenge to develop needle-free technologies that provide cost-effective solutions for safe, reliable and controlled delivery of pharmaceutical materials in a range of different scenarios, including for self-administration with the minimum of training, such as that offered by the Glide SDI™. Read more... |
 |
||
|
|
||
 |
Company Profiles3M Drug Delivery Systems, Aegis Therapeutics, Glide Pharma, Phares Drug Delivery |
||
|
|
||
Drug Delivery OpportunitiesDo you know about our drug delivery opportunities database? If you're interested in gaining visibility for your opportunity without giving away too much information, you should register with us now! Information about your opportunity will be posted on the website without detailing your firm's name, thereby protecting your business opportunity. Only those firms which are truly interested in your opportunity will gain access to your valuable product information.For the latest information about our Drug Delivery Opportunities, visit our website or alternatively, request a password to submit your opportunity online. Featured Opportunity Adenovector-Based Vaccines Administrative Route - Intramuscular, Nasal, Subcutaneous Indication - Delivery of antigens to antigen-presenting cells Licence code - LO-0406-37 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Autumn / Winter 2006For deal makers actively assessing drug delivery technologies, the current complimentary issue of the Drug Delivery Report is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail enquiries@pharmaventures.com with the words UNSUBSCRIBE DDR as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail enquiries@pharmaventures.com with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@pharmaventures.com